Skip to main content
Premium Trial:

Request an Annual Quote

Tripos Ceases Trading, Begins Liquidation of Assets

NEW YORK (GenomeWeb News) - Tripos yesterday ceased trading its shares and began to liquidate its assets, moves which are in line with plans the company laid out after selling both of its revenue-generating businesses earlier this year.
Tripos sold its Discovery Research business to Commonwealth Bio in May for as much as $2.15 million and it sold its Discovery Informatics business to Vector Capital in March for $26 million. 
Today, Mellon Investor Services will begin an initial a distribution of $.47 a share to Tripos shareholders.
Tripos said it has formed a liquidating trust that will dispose of remaining assets and liabilities following the initial distribution. The company estimates these assets to be worth around $4 million, primarily in cash.
In addition to the cash distribution, all shareholders will receive a "beneficial interest" in the liquidating trust.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.